< 1 minute read
Dec. 16, 2021

Giredestrant: Oral Selective Estrogen Receptor Degrader (SERD) and Full Antagonist

giredestrant

selective ER degrader (SERD) + full antagonist oral (30 mg QD), Ph. III for ER+, HER2- BC from profiling >4k cmpds for desired MoA Journal of Medicinal Chemistry Genentech, San Francisco, US

drughunter.com
Drug Hunter Team

The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545) , is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third SERD clinical candidate from Genentech (after GDC-0810 and GDC-0927) and a number of oral SERDs have previously [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in